Pikralida
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
Pikralida is a science-driven & result-focused clinical-stage biotech based in Poland (EU), advancing innovative therapies for unmet medical needs. Our lead molecule, PKL-021 (marimastat), is a potent MMP inhibitor with confirmed human safety and a validated mechanism of action. The company is progressing four programs: three Phase II-ready therapies in stroke, traumatic brain injury (TBI), and human snakebite envenoming, along with a fourth project – a veterinary formulation for snakebite – currently on a fast-track path to market. All projects share a focus on rapid intervention and neuroprotection, with strong first-in-class and dual-use potential.
Pikralida is currently seeking co-development and commercial partners for several of its assets.
#rediscovery
#first-in-class
#dual-use
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}